We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Zetia Buyers Demand Info On Generics In Pay-For-Delay Suit

Law360 (May 17, 2019, 2:44 PM EDT) -- Generic-drug maker Zydus needs to cough up details on its generic version of Zetia, buyers of the cholesterol medication told a Virginia federal court, as they contend that information may bolster their pay-for-delay case against Merck and Glenmark.

The purchasers said in a filing Thursday that Zydus Pharmaceuticals USA Inc. is the lone holdout among a slew of generic-drug makers they subpoenaed for information in the sweeping litigation accusing Merck & Co. Inc. and Glenmark Pharmaceuticals Inc. of working to keep generic Zetia rivals off the market.

Merck and Glenmark are accused of striking a decade-old deal that would see Glenmark...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS